CEL-SCI Corporation Stock News

Stocks Analysis by Harry Boxer covering: Kamada, Allied Healthcare Products Inc, Dynavax Technologies Corporation, Lakeland Industries Inc. Read Harry Boxer's latest article on Investing.com

CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series

The power stations in Port Talbot and Newport are continuing to operate

CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series

State Street Corp lifted its stake in shares of CEL-SCI Co. (NYSEAMERICAN:CVM) by 8.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5

One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev

Rhumbline Advisers raised its position in shares of CEL-SCI Co. (NYSEAMERICAN:CVM) by 47.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Comm

By John Vandermosten NYSE:CVM READ THE FULL CVM RESEARCH REPORT Second Quarter Fiscal Year 2020 Operational and Financial Results CEL-SCI Corporation (NYSE:CVM) reported second quarter fiscal year 202

Phase III trial recently ended. Top line data results very soon. SEER data points to success. Price target $200 upon approval.

Cel-Sci has been dragging a drug trial on for years which should have been stopped in 2014 on the recommendation of their Independent Data Monitoring Committee.

CEL-SCI Corporation reports second quarter fiscal 2020 financial results.

CEL-SCI Corporation reports second quarter fiscal 2020 financial results.

By John Vandermosten, CFA NYSE:CVM CEL-SCI Corporation (NYSE:CVM) announced on May 4, 2020 that it had achieved the targeted number of events for its IT MATTERS trial for head and neck cancer. The tri